Skip to content

Efficacy of recombinant human soluble thrombomodulin for disseminated intravascular coagulation (DIC) occurred in patients with severe sepsis

Efficacy of recombinant human soluble thrombomodulin for disseminated intravascular coagulation (DIC) occurred in patients with severe sepsis - Efficacy of recombinant thrombomodulin for patients with severe sepsis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000008339
Enrollment
100
Registered
2012-08-01
Start date
2012-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe sepsis with disseminated intravascular coagulation (DIC)

Interventions

The rhTM group When the patients with severe sepsis are diagnosed DIC (the acute DIC), they are injected intravenously with recombinant human soluble thrombomodulin (rhTM) within 24 hrs after the dia
Surviving sepsis campaign 2008&quot
on the patients in both the rhTM group and the control group.

Sponsors

The ethics committees of National Center For Global Health and Medicine, Japan
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) The patients with severe sepsis or septic shock admitted to the National Center For Global Health and Medicine, Japan 2) 1) and the patients were diagnosed DIC using the acute DIC criteria within 24 hrs after the admission.

Exclusion criteria

Exclusion criteria: 1. The patients who have the need for the emergency surgery. 2. The patients and/or their family who refuse the intensive care (intratracheal intubation, mechanical ventilation, administration of catecholamine, etc.). 3. The patients who have intracranial bleeding, pulmonary hemorrhage, gastrointestinal hemorrhage (persistent hematemesis, persistent hemorrhagic stool or persistent bleeding from gastrointestinal ulcer). 4. The patients who have fulminant hepatic failure, decompensated cirrhosis, or other sever hepatic diseases. 5. The patients who have allergies to rhTM 6. The pregnant women, or the patients who have the possibility of pregnancy.

Design outcomes

Primary

MeasureTime frame
the survival rate after the 28 hospital days and 3 month.

Secondary

MeasureTime frame
1. SOFA score, MODS score 2. CRP value, platelet value, FDP value, D-dimer value 3. Duration of administration of catecholamine 4. Total fluid value until stopping administration of catecholamine 5. The volume of blood transfusion until 72 hours and the total volume until the discharge (RBC volume, FFP volume, platelet volume) 6. Duration of mechanical ventilation 7. The survival rate of 72 hours

Countries

Japan

Contacts

Public ContactAkiyoshi Hagiwara

National Center For Global Health and Medicine, Japan Emergency Medicine and Critical Care

ahagiwar@hosp.ncgm.go.jp03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026